BeStock  
Stocks › Biotechnology › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2621Biotechnology
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

NAMS at a glance

Shares of NewAmsterdam Pharma are down 5.64% at $18.41. The company is worth $2.21B, number 2621 out of 3753 on our list.

It is close to the bottom of its 52-week range ($17.90 to $42.21), 56.4% under the high. Holders are behind 51.9% over twelve months, and down 31.4% across the last three months.

On the chart it has slipped under both the 50-day ($21.09) and 200-day ($28.84) moving averages; RSI is 38, and the last 30 sessions moved at roughly 64% annualized volatility.

In the quarter ended Sep 2026 the company brought in $19.16M of revenue, up 5,406.9% from a year earlier, and a net loss of $17.39M.

10 analysts follow the stock and the average call is "buy". The mean target, $54.44, sits 195.7% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$18.25 / $23.00
Average price today$18.81
Volume1.75MAvg (90d) 1.50M
Turnover$32.82M
Turnover rate2.13%of shares outstanding
Volume ratio1.03vs. recent average pace
Day amplitude7.66%
Market cap$2.21B
Float market cap$1.51B
Shares outstanding81.84M
EPS (TTM)-$1.72
P/B3.50
Book value / share$5.26
Net profit (TTM)-$206.28M
Net assets$630.83M
30-day volatility64.1%annualized
Avg daily range (ATR)7.39%of price, 14 days
Max drawdown (1y)-55.6%-55.6% from 1y peak

Quote as of Nov 20, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

B
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

10 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 22.5 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability3.9
Momentum5.6
Financial health77.4
Analyst view96.8

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$54.44+195.7% vs. current price
Consensus ratingBuy10 analysts covering
Morningstar fair value$25.71Price is below fair value

Wall Street’s average 12-month target is $54.44, 195.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $25.71, so shares trade 28.4% below that estimate. On earnings multiple, it sits in the 27th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-5.6%
1 week
-8.6%
1 month
-14.7%
3 months
-31.4%
6 months
-48.1%
Year to date
-47.5%
1 year
-51.9%
Day range
$18.29$19.78
52-week range
$17.90$42.21

Technical signals

Full technicals →
Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-6.9%Bearish
Price vs 50-day average-12.7%Bearish
Price vs 200-day average-36.2%Bearish
50-day vs 200-day50d below 200dBearish
RSI (14)38.4Bearish
MACD (12,26,9)-0.58Bullish
Bollinger band position4%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How NAMS ranks on BeStock

Market value#2610 of 3734
Closeness to 52-week high#3222 of 3724
Dollar volume today#1698 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

NAMS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on NAMS.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on NAMS

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

NAMS stock: common questions

How is NewAmsterdam Pharma stock doing today?

$18.41 is the latest print for NAMS, a move of -5.64% against yesterday's close of $19.51. Today's low and high so far: $18.29 and $19.78.

How large is NewAmsterdam Pharma by market value?

Equity value comes to $2.21B at the current price. By that measure it is number 2621 of the 3753 names in our coverage.

Is NAMS near its 52-week high or low?

The year's floor is $17.90 and the ceiling $42.21. Shares are 56.4% away from that ceiling.

Does NewAmsterdam Pharma pay a dividend?

Our data shows no dividend paid by NewAmsterdam Pharma over the trailing twelve months.

Is NAMS rated a buy by Wall Street?

Of 10 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $54.44, with the most cautious at $42.00 and the most optimistic at $61.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on NAMS.

Sign in to join the discussion.

Scroll to Top